Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
ConclusionsFirst-line osimertinib treatment resulted in a clinically meaningful PFS and OS benefit versus comparator EGFR TKI in Chinese patients with EGFRm advanced NSCLC. Safety data were consistent with the known safety profile of osimertinib.Clinical Trial RegistrationClinicalTrials.gov NCT02296125, registered 20 November 2014
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Clinical Trials | Computers | Laboratory Medicine | Lung Cancer | Non-Small Cell Lung Cancer | Study | Tarceva | Toxicology